This year marked the 37th Annual Transcatheter Cardiovascular Therapeutics conference, and while the core of the conference is still catheter-based heart therapies, this year’s research studies and device demonstrations made it clearer than ever that cardiac medtech continues to push the boundaries of what can be done with a catheter.
Structural Heart is King – The biggest research and booth presence at this year’s TCT came from valve replacement technologies, underscoring just how much the field of transcatheter valve replacements has grown, with TAVR now being just one of many valve replacement procedures available through the minimally invasive method.
Coronary Therapies are a Close Second – Though a lot of the excitement is around valve replacements, innovations in percutaneous coronary intervention, coronary revascularization, and intravascular lithotripsy all featured heavily, showing just how central coronary artery disease is to interventional cardiology.
Imaging Solutions For Less Catheterization – With the increases in catheter-based heart procedures, many companies are now developing “wire-free” ways to help cardiologists plan interventions, reducing the paradox of needing a catheter to figure out if you need a catheter.
Improving the Cath Lab – In the same vein, once care teams are in the cath lab, companies like Egg Medical and Rampart both showed several ways to improve physical safety by blocking radiation exposure through adjustable patient tables and ultra-lightweight lead vests.
AI at TCT Focused on Planning over Diagnosis – Early on in 2025, cardiology conferences like ACC and HRS were full of news and studies about cardiology AI technology changing the way we diagnose heart disease, yet the exhibitors and research at TCT 2025 took a more procedural approach to AI for transcatheter therapies, with the majority of use-cases focusing on planning TAVR or PCI.
